Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Case Scenario: Stage 3A High-Grade Epithelial Ovarian Cancer

January 27th 2022

Chad A. Hamilton, MD, and Robert W. Holloway, MD, review the case of a 57-year-old woman with stage IIIA high-grade epithelial ovarian cancer.

FDA Grants Fast Track Status to CX-5461 for Breast and Ovarian Cancers With BRCA1/2, PALB2, or Other HRD Mutations

January 25th 2022

The FDA has granted a fast track designation to CX-5461 (Pidnarulex) as a potential therapeutic option for patients with breast and ovarian cancers that harbor BRCA1/2, PALB2, or other homologous recombination deficiency mutations.

Dr. Gershenson on the Results of the MILO Trial in Low-Grade Serous Ovarian Cancer

January 24th 2022

David M. Gershenson, MD, discusses the results of the phase 3 MILO trial in low-grade serous ovarian cancer.

Genetic Counseling for Ovarian Cancer

January 20th 2022

Oncologists debate the need for genetic counseling for ovarian cancer patients and how to approach molecular testing alongside neoadjuvant chemotherapy.

Sequencing of Biomarker Testing for Ovarian Cancer

January 20th 2022

Dr Robert W. Holloway explains his typical approach to ovarian cancer biomarker testing and sequencing.

Nivolumab Misses Mark in Japanese Patients With Platinum-Resistant Ovarian Cancer

January 18th 2022

Nivolumab did not significantly improve overall survival compared with chemotherapy in Japanese patients with platinum-resistant ovarian cancer.

STRO-002 Produces Deep Responses in Heavily Pretreated Advanced Ovarian Cancer

January 7th 2022

The FolRα-targeted antibody-drug conjugate STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced ovarian cancer.

Aggarwal Shines a Light on Precision Medicine in Lung, Breast, Ovarian, and GI Cancers

January 6th 2022

Molecular testing is an established and essential precursor to treatment for patients with non–small cell lung cancer based on the volume of actionable targets, such as EGFR and KRAS G12C mutations, as well as PD-L1 status.

Dr. Monk on the Emergence of NaPi2b as a Target in Ovarian Cancer

January 5th 2022

Bradley J. Monk, MD, FACS, discusses the emergence and utility of NaPi2b as a target in ovarian cancer.

Penson Provides a Snapshot View of Switch Maintenance Therapy Selection in Recurrent Ovarian Cancer

January 4th 2022

Richard Penson, MD, MBBS, discusses how he makes treatment decisions for maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer.

HRD Status Drives Decisions With Frontline PARP Inhibition in Advanced Ovarian Cancer

January 4th 2022

Anil K. Sood, MD, provides insight into his approach toward the frontline maintenance treatment of women with advanced ovarian cancer.

Molecular Testing and Ovarian Cancer

December 22nd 2021

Chad A. Hamilton, MD, and Robert W. Holloway, MD, discuss challenges clinicians face in treating ovarian cancer and review the current state of biomarker testing.

Dr. Sood on Navigating Frontline Maintenance Therapy in Ovarian Cancer

December 17th 2021

Anil K. Sood, MD, discusses navigating frontline maintenance therapy in ovarian cancer.

Dr. Penson on PARP Inhibitors as Switch Maintenance Therapy in Recurrent Ovarian Cancer

December 17th 2021

Richard T. Penson, MD, MRCP, discusses selecting between PARP inhibitors for switch maintenance therapy in recurrent ovarian cancer.

Dr. Erickson on the Varying Safety Profiles of Select PARP Inhibitors in Ovarian Cancer

December 7th 2021

Britt Erickson, MD, discusses the toxicity profiles of available PARP inhibitors used in the treatment of patients with ovarian cancer.

Dr. Rose on the Importance of Genetic Testing in Ovarian Cancer

December 2nd 2021

Stephen L. Rose, MD, UW Health, discusses the importance of genetic testing in ovarian cancer.

Dr. Thaker on the Importance of Surveying Patients on Unmet Needs in Ovarian Cancer

December 2nd 2021

Premal Thaker, MD, MS, discusses the importance of surveying patients on unmet needs in ovarian cancer.

Dr. Shah on the Significance of PARP Inhibitors in Ovarian Cancer

November 30th 2021

Payal D. Shah, MD, discusses the significance of the emergence of PARP inhibitors in ovarian cancer.

Niraparib Demonstrates PFS Benefit in Chinese Population With Advanced Ovarian Cancer

November 30th 2021

First-line maintenance treatment with the PARP inhibitor niraparib yielded a clinically meaningful and statistically significant improvement in progression-free survival vs placebo in Chinese patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status, according to data from the phase 3 PRIME trial.

Mirvetuximab Soravtansine Shows Promising Topline Results in FRα-High, Platinum-Resistant Ovarian Cancer

November 30th 2021

The antibody-drug conjugate mirvetuximab soravtansine has shown promising response rates and a favorable toxicity profile in patients with folate receptor alpha-high, platinum-resistant ovarian cancer who have received previous treatment with bevacizumab.